News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
888,500 Results
Type
Article (89133)
Company Profile (556)
Press Release (798793)
Multimedia
Podcasts (256)
Webinars (39)
Section
Business (267196)
Career Advice (4169)
Deals (40066)
Drug Delivery (189)
Drug Development (91867)
Employer Resources (208)
FDA (18644)
Job Trends (17514)
News (399098)
Policy (40029)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (4)
2027 Genetown Standard (7)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (3074)
Academic (2)
Accelerated approval (63)
ADA (50)
Adcomms (43)
Allergies (216)
Alliances (56991)
ALS (252)
Alzheimer's disease (2064)
Antibody-drug conjugate (ADC) (626)
Approvals (19079)
Artificial intelligence (970)
ASCO (345)
Autoimmune disease (407)
Automation (71)
Bankruptcy (410)
Best Places to Work (12635)
BIO (81)
Biologics (1)
BIOSECURE Act (23)
Biosimilars (273)
BioSpace Insights (241)
Biotechnology (337)
Bladder cancer (227)
Brain cancer (87)
Breast cancer (887)
Cancer (7042)
Cardiovascular disease (601)
Career advice (3611)
Career pathing (58)
CAR-T (408)
CDC (77)
Celiac Disease (3)
Cell therapy (1137)
Cervical cancer (60)
Clinical research (79715)
Collaboration (2580)
Commercialization (8)
Company closure (9)
Compensation (1681)
Complete response letters (121)
COVID-19 (3054)
CRISPR (133)
C-suite (1449)
Cystic fibrosis (173)
Data (9309)
Decentralized trials (3)
Denatured (99)
Depression (212)
Dermatology (117)
Diabetes (746)
Diagnostics (7738)
Digital health (77)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (496)
Drug pricing (248)
Drug shortages (39)
Duchenne muscular dystrophy (354)
Earnings (103466)
Editorial (82)
Employer branding (25)
Employer resources (178)
Events (139341)
Executive appointments (1282)
FDA (23118)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (25)
Frontotemporal dementia (37)
Funding (2106)
Gene editing (291)
Generative AI (100)
Gene therapy (895)
GLP-1 (1321)
Government (5580)
Grass and pollen (8)
Guidances (434)
Healthcare (21295)
Hematology (198)
HIV (110)
Huntington's disease (74)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (128)
Immunology and inflammation (382)
Immuno-oncology (126)
Indications (239)
Infectious disease (3475)
Inflammatory bowel disease (249)
Inflation Reduction Act (17)
Influenza (157)
Intellectual property (352)
Interviews (824)
IPO (18035)
IRA (61)
Job creations (5209)
Job search strategy (2876)
JPM (73)
Kidney cancer (27)
Labor market (131)
Layoffs (705)
Leadership (57)
Legal (10175)
Licensing (12)
Liver cancer (112)
Longevity (39)
Lung cancer (936)
Lymphoma (508)
Machine learning (70)
Management (69)
Manufacturing (1372)
Marketing (15)
MASH (235)
Medical affairs (1)
Medical device (15359)
Medtech (15596)
Mergers & acquisitions (23449)
Metabolic disorders (1929)
mRNA (287)
Multiple sclerosis (218)
NASH (24)
Neurodegenerative disease (563)
Neuropsychiatric disorders (139)
Neuroscience (3974)
Neurotech (2)
NextGen: Class of 2026 (7718)
Non-profit (5154)
Now hiring (89)
Obesity (913)
Opinion (386)
Ovarian cancer (260)
Pain (304)
Pancreatic cancer (386)
Parkinson's disease (447)
Partnered (45)
Patents (727)
Patient recruitment (896)
Peanut (73)
People (68430)
Pharmaceutical (81)
Pharmacy benefit managers (38)
Phase 1 (24615)
Phase 2 (34620)
Phase 3 (26040)
Pipeline (11414)
Policy (411)
Postmarket research (3561)
Preclinical (11033)
Press Release (72)
Prostate cancer (372)
Psychedelics (86)
Radiopharmaceuticals (394)
Rare diseases (1414)
Real estate (7467)
Recruiting (83)
Regulatory (31000)
Reports (84)
Research institute (2792)
Resumes & cover letters (655)
Rett syndrome (50)
RNA editing (32)
RSV (101)
Schizophrenia (204)
Series A (359)
Series B (265)
Service/supplier (16)
Sickle cell disease (136)
Special edition (34)
Spinal muscular atrophy (194)
Sponsored (55)
Startups (4379)
State (2)
Stomach cancer (21)
Supply chain (154)
Tariffs (105)
The Weekly (154)
Vaccines (1355)
Venture capital (150)
Weight loss (619)
Women's health (157)
Worklife (25)
Date
Today (94)
Last 7 days (651)
Last 30 days (2697)
Last 365 days (33450)
2026 (21126)
2025 (33213)
2024 (37865)
2023 (42564)
2022 (53928)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1301)
Alabama (107)
Alaska (7)
Arizona (433)
Arkansas (16)
Asia (52611)
Australia (9254)
California (15325)
Canada (4281)
China (1741)
Colorado (658)
Connecticut (679)
Delaware (472)
Europe (121359)
Florida (2321)
Georgia (497)
Hawaii (5)
Idaho (70)
Illinois (1333)
India (123)
Indiana (702)
Iowa (27)
Japan (661)
Kansas (150)
Kentucky (60)
Louisiana (66)
Maine (94)
Maryland (1836)
Massachusetts (11183)
Michigan (440)
Minnesota (858)
Mississippi (7)
Missouri (174)
Montana (37)
Nebraska (31)
Nevada (163)
New Hampshire (92)
New Jersey (4043)
New Mexico (37)
New York (4032)
North Carolina (2020)
North Dakota (11)
Northern California (7708)
Ohio (483)
Oklahoma (30)
Oregon (48)
Pennsylvania (2979)
Puerto Rico (33)
Rhode Island (55)
South America (1671)
South Carolina (93)
South Dakota (2)
Southern California (6058)
Tennessee (253)
Texas (2500)
United States (54639)
Utah (465)
Vermont (2)
Virginia (384)
Washington D.C. (88)
Washington State (1240)
West Virginia (4)
Wisconsin (169)
Wyoming (2)
888,500 Results for "ela medical s a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cystic fibrosis
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
August 10, 2026
·
2 min read
·
Michael Gibney
Insights
Austria’s new growth fund could further bolster its dynamic biotech innovation economy
The national growth vehicle isn’t biotech‑dedicated, but channeling capital toward life sciences would amplify Austria’s strong research hubs, nondilutive funding landscape and reputation as a champion in science and technology.
August 11, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Business
Sanofi’s R&D head exits, with AI biotech Xaira’s exec stepping in
About two months into CEO Belén Garijo’s new tenure, Sanofi’s R&D chief has departed, with Xaira’s chief medical officer set to take charge of the pharma’s pipeline.
June 22, 2026
·
1 min read
·
Gabrielle Masson
Earnings
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.
August 5, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
May 5, 2026
·
4 min read
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
July 13, 2026
·
4 min read
·
Heather McKenzie
Psychedelics
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals.
July 24, 2026
·
3 min read
·
Gabrielle Masson
Parkinson’s disease
BioVie shares halve on murky Parkinson’s disease readout
BioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.
August 6, 2026
·
3 min read
·
Gabrielle Masson
Obesity
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.
August 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)
July 30, 2026
·
1 min read
1 of 88,850
Next
